Acelyrin, Inc. (SLRN) Value Adjusted for Debt and Cash

Acelyrin, Inc. (SLRN) focuses on creating advanced anti-inflammatory treatments by investing in the development of isokibart. The asset value tracked on the chart, which currently stands at , is subject to the influence of geopolitical disruptions that hinder global testing and logistics. Meanwhile, pricing power will remain latent until the arthritis drug confirms its superiority over analogs during trials.

SLRN (acelyrin.com) Total Company Value history from 07/04/2022 to 10/28/2026

Acelyrin, Inc. (SLRN) - metric breakdowns and financial figures

- price and consensus price forecast:
Price Chart Acelyrin Inc.|SLRN - Price Target Chart
- market capitalization data:
Market Value ACELYRIN|SLRN - Total Company Value
- book capitalization data:
Equity per Share ACELYRIN|SLRN - Company Book Value|Market Capitalization to Net Assets acelyrin.com|SLRN - Company Total Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Acelyrin, Inc.|SLRN - Long-Term Debt to Capital|Short-Term Debt to Capital acelyrin.com|SLRN - Company Debts|Debt to Net Assets Ratio ACELYRIN
Comprehensive company analysis:Acelyrin Inc. (SLRN)

For an investor, assessing the stability of Acelyrin, Inc. (SLRN) depends directly on weighing the costs of business acquisition against the potential for market monopolization of immunological drugs. When analyzing the total asset value, one must consider the sum of market capitalization and debt minus cash, which reflects the actual buyout price of the company. The dynamics of this indicator allow investors to filter out market noise and evaluate the fundamental value of this innovative bio-business.

Competitor analysis for Acelyrin, Inc.

Haleon PLC - Total Company Value|Total Company Value Kenvue Corp (KVUE)|VRNA: Value Adjusted for Debt and Cash|Total Company Value Jyong Biotech Ltd|LGND (ligand.com) - Business Value|Total Company Value Amneal AMRX|Full Business Value Perrigo Company PLC|Alvotech Corp (ALVO) - Enterprise Value|Value Adjusted for Debt and Cash Liquidia Inc. (LQDA)|Enterprise Value GLPG (Galapagos NV)|anipharmaceuticals.com - Enterprise Value|Total Company Value MannKind (MNKD)|AMPH: Value Adjusted for Debt and Cash|PCRX (Pacira) - Total Company Value|ARS Corp (SPRY) - Real Price to Acquire Entire Company|TBPH (Theravance Biopharma) - Enterprise Value|Enterprise Value aquestive.com (AQST)|scPharmaceuticals Inc. (SCPH) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash TECX (tectonictx.com)|TNXP: Total Company Value|SXTC - Total Enterprise Value|Real Price to Acquire Entire Company Eupraxia Pharma EPRX|BHST - Aggregate Business Value|Enterprise Value eXoZymes EXOZ|Oramed Pharmaceuticals Inc. (ORMP) - Value Adjusted for Debt and Cash|Enterprise Value ENTX (Entera Bio Ltd)|Total Enterprise Value HYFT|ABVC BioPharma (ABVC) - Total Company Value|Value Adjusted for Debt and Cash cumberlandpharma.com (CPIX)|Enterprise Value QNTM (Quantum BioPharma)|Enterprise Value FibroGen Inc FGEN|TELO: Enterprise Value|RANI - Real Price to Acquire Entire Company|Enterprise Value SNYR|RLYB (Rallybio) - Total Enterprise Value|Total Company Value Lexaria Bioscience Corp|Total Company Value Pulmatrix Inc (PULM)|Pheton Holdings Ltd - Real Price to Acquire Entire Company|Total Enterprise Value APM (aptorumgroup.com)|Total Company Value Lyra Therapeutics, Inc.|Value Adjusted for Debt and Cash Impact BioMedical, Inc. IBO|Enterprise Value TNFA (TNF Pharma)|YCBD: Company Buyout Price|Total Company Value PainReform Limited|Business Value Altamira Therapeutics Ltd.|LIPO - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash optinose.com|PIRS (Pieris Pharmaceuticals, Inc.) - Enterprise Value|Company Buyout Price PROC (Procaps Group)|PTPI - Total Company Value|Business Value Qilian International Corp QLI|TFFP: Enterprise Value